What Kentucky Bioprocessing does

Kentucky Bioprocessing is a privately held for-profit bioprocessing company headquartered in Owensboro, Kentucky, established in 2006. The firm describes itself in its firmographic record as 'a global leader in the expression, extraction, and commercialization of proteins and other plant-derived products,' indicating a focus on plant-based protein expression platforms and downstream extraction and purification workflows targeting pharmaceutical, research, or industrial biotechnology end-users.

The company operates with 11-50 employees, an organizational footprint consistent with a specialized contract development or contract manufacturing organization serving external clients. Plant-derived protein expression is a well-established modality used to produce therapeutic proteins, vaccines, enzymes, and research-grade biologics through hosts such as tobacco, moss, or carrot cell suspensions, and the firm's positioning suggests it operates at commercial scale rather than purely academic scale. Given the explicit mention of 'commercialization,' the firm appears to take products partway or fully through to market or supply customers with finished protein and plant-derived materials, not merely perform toll processing.

No financial disclosures, named customer logos, pricing models, ownership structure, partnership history, M&A activity, funding rounds, regulatory milestones, or leadership-team composition were available in the provided source material. The company's public website content was not substantively retrievable beyond a privacy notice, and structured firmographic fields for technology, products, customer segments, and revenue model were all empty. Consequently, the business model is best characterized as specialized bioprocessing services priced via custom contracts (consistent with industry norms), but specific go-to-market mechanics, customer mix, segment split, and revenue concentrations are unverified and represent material due diligence gaps.

Name

Kentucky Bioprocessing

Website

https://kentuckybioprocessing.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Kentucky Bioprocessing is a privately held Owensboro, Kentucky-based bioprocessing firm founded in 2006 that focuses on the expression, extraction, and commercialization of proteins and other plant-derived products for external life sciences customers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

akta.pro secondary industry

Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)

Keywords

• Plant-based bioprocessing
• Protein expression services
• Biologics contract manufacturing
• Plant-derived protein production
• Tobacco expression platform

Headquarters

HQ city

Owensboro

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Core offering

Kentucky Bioprocessing provides contract bioprocessing services focused on the expression, extraction, and commercialization of proteins and other plant-derived products. Using plant-based production platforms, it manufactures biologics and protein products on behalf of clients across pharmaceutical, animal health, and industrial biotechnology sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Plant-based protein expression services Contract expression of proteins and other plant-derived products using plant-based (tobacco-plant) transient expression platforms on behalf of pharmaceutical, animal health, and industrial biotech clients.
• Protein extraction and purification services Extraction and purification of proteins and other target molecules from plant biomass produced via the company's plant-based expression systems.
• Commercialization of plant-derived products Scale-up manufacturing and commercialization support for plant-derived protein products, taking client programs from development through commercial supply.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Protalix Biotherapeutics: Protalix is a clinical and commercial-stage company producing biologics via a plant-cell (carrot cell) expression platform, sharing the plant-based manufacturing concept with KBP but operating as a product developer rather than a pure CDMO.
• Samsung Biologics: Samsung Biologics is a large-scale mammalian biologics CDMO competing for the same sponsor CDMO contracts and RFP processes that plant-based CDMOs like KBP target.
• Lonza Biologics: Lonza is a leading global CDMO offering mammalian and microbial biologics manufacturing at commercial scale; while KBP uses plant-based platforms, both compete for the same biologics CDMO wallet.
• Catalent: Catalent is a major global biologics and gene therapy CDMO offering mammalian cell-based drug substance manufacturing, representing the mainstream alternative that KBP's plant-based platform is positioned against.

Direct peers

• iBio: iBio operates a plant-based biopharmaceutical contract development and manufacturing platform (Bryant and FastPharming systems), directly competing with Kentucky Bioprocessing in plant-derived protein expression and biologics CDMO services.
• Leaf Expression Systems: Leaf Expression Systems provides contract development and manufacturing services using a Nicotiana-based plant expression platform for biologics and vaccines, competing head-to-head with KBP in plant-derived protein production.
• CapeBio Technologies: CapeBio is a plant-based biomanufacturing CDMO offering protein expression and reagent production in Nicotiana benthamiana, directly comparable to KBP's plant-derived protein expression and extraction services.

Others

• Fraunhofer Institute for Molecular Biology and Applied Ecology (IME): Fraunhofer IME provides plant-based biopharmaceutical research, process development, and manufacturing services through transient plant expression, representing an academic/not-for-profit alternative entrant in the same technology category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kentucky Bioprocessing